Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+55.5%
5Y CAGR+36.1%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+55.5%/yr
Annual compound
5Y CAGR
+36.1%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
4.7x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 267.22% |
| 2024 | -73.88% |
| 2023 | 68.03% |
| 2022 | 71.08% |
| 2021 | -129.16% |
| 2020 | 57.12% |
| 2019 | -164.06% |
| 2018 | -73.60% |
| 2017 | -196.98% |
| 2016 | 210.49% |